Hospital-acquired, ≥ 4 days hospitalization

- Majority of cases occur in second week of hospitalization.

- Risk factors:

  • mechanical ventilation

  • facial/cranial fractures

  • nasal packing

  • nasogastric/nasoendotracheal tubes

  • otitis media post head trauma

  • corticosteroid therapy

  • prior antibiotic use.

- Black, necrotic tissue or discharge in patients with poorly controlled diabetes/ketoacidosis, or with significant immunosuppression, may indicate mucormycosis. Recommend urgent ENT/ID consult.

- Recommend:

  • ENT consult
  • Remove nasogastric/nasoendotracheal tube
  • Semi-recumbent (30-45°) positioning
  • Sinus aspiration for C&S:
    • tailor antibiotics to C&S results.

- If no response to therapy in 7 days, insertion of a drainage catheter should be considered.

 
Usual Pathogens

Enterobacterales
P. aeruginosa
Acinetobacter spp
S. aureus/MRSA
Yeast

 

Empiric Therapy Dose Duration
Clindamycin IV/PO 600mg IV q8h/
300mg PO qid
7-10 days
+    
Ciprofloxacin IV/PO 400mg IV q12h/
750mg PO bid
 

Severe

Empiric Therapy Dose Duration
Piperacillin-tazobactam 4.5g IV q6h 7-10 days

or

Facial fractures, head trauma, CNS infection/meningitis suspected

Empiric Therapy Dose Duration
Meropenem 2g IV q8h 7-10 days